An Open-label, Uncontrolled Study of ONO-4578 and ONO-4538 in Combination With Standard-of-care Docetaxel and Ramucirumab as Second-line Therapy in Patients With Advanced or Recurrent Non-small Cell Lung Cancer
Clinical trial NCT06542731 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT06542731
- Sponsor
- Ono Pharmaceutical Co., Ltd.
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2021-06-01
- Primary completion
- 2026-09-12
- Enrollment
- 42
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.